About this trial
The plasma filter is applied for a single use in extracorporeal blood purification therapy. The intended purpose is the separation of plasma from blood by filtration, in conditions, which are associated with increased concentration of plasma components where a rapid depletion slows down or stops a pathogenic process.
The investigation involves the collection of treatment data of the new Plasma Filter PX2 in combination with the multiFiltrate and multiFiltratePRO in therapeutic plasma exchange (TPE) treatments. The multiFiltrate and multiFiltratePRO are devices for extracorporeal blood purification treatments. No further control treatments will be investigated in this one arm design. The design is considered to be appropriate to reflect daily clinical practice and to contribute to empirical evidence of performance of the new Plasma Filter PX2. No specific treatment schedule is defined by the study protocol. The TPE treatment is performed with the plasma filter PX2 (investigational device) according to clinical practice established in each of the participating centers and are prescribed at the discretion of the treating physician. The participation in the study will have no influence on the treatment plan. The documentation of the treatment includes the therapy up to the tenth (10th) treatment.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Informed consent signed and dated by study patient and investigator/authorized physician
Minimum age of 18 years
Patients with an indication for a therapeutical plasma exchange
Patients to be treated with the plasma filter PX2 in combination with the multiFiltrate or multiFiltratePRO
Disqualifiers
Patients with known or suspected hypersensitivity to any of the materials of the PX2 plasma filter (Polysulfone, Polyvinylpyrrolidone, Polypropylene, Polyurethane, Silicone) and trial related products
Patients suffering from a heparin allergy
Patients with a prescription for TPE treatment with the completion of < 0.8 PV and > 2.0 PV
Any conditions which could interfere with the patient's ability to comply with the study
Trial design
Single group
Treatments tested in this trial
Therapeutic Plasma Exchange (TPE) with the Plasma Filter PX2
Device230 evaluable TPE treatments will be documented in the study (with an average of 5-7 TPE treatments per patient this corresponds to approximately 46 patients)
Treatment groups
Trial outcomes
Primary outcomes
Analysis of TPE treatments with the Plama Filter PX2
Investigation of clinical performance of the new plasma filter PX2 by assessing the completion of the prescribed plasma volume (PV) in ≥ 75% of all TPE procedures
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Fresenius Medical Care Deutschland GmbH
Lead sponsor
Alcedis GmbH
Collaborator